About Schon Pharmaceuticals
Schon Pharmaceuticals is a Healthcare company based in Indore (India). It operates as a manufacturer of syrup, capsules, tablets, injecatables and ointment. It operates on a Traditional Pharmaceuticals model. The company has 77 employees. Its chief executive is Anil Bhatia. Its Indian entity Schon Pharmaceuticals Limited reported revenue of ₹35.42 Cr. Schon Pharmaceuticals offers products and services including Schon Pharmaceuticals Platform. Its focus areas include Traditional Pharmaceuticals, Generics, Companies and Diversified.
Company details
Schon Pharmaceuticals manufacturer of syrup, capsules, tablets, injecatables and ointment through providing healthcare solutions, traditional pharmaceuticals, traditional pharmaceuticals, and providing healthcare solutions. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Indore, India
- Employees 77
- SectorsHealthcare
- Website schonpharma.in
- Legal Name Schon Pharmaceuticals Limited
- Date of Incorporation 30 Sep, 1994
- Jurisdiction Indore, Madhya Pradesh, India
- Annual Revenue₹35.42 Cr
FY 2024 · +7% YoY
- Net Profit₹57.1 Lakh
FY 2024 · 2% margin
- EBITDA₹2.13 Cr
FY 2024 · 6% margin
- Employee Count77
Associated legal entities of Schon Pharmaceuticals
Schon Pharmaceuticals operates through Schon Pharmaceuticals Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Schon Pharmaceuticals Limited CIN U24231MP1994PLC007829 | Active | 30 Sep 1994 | Indore, Madhya Pradesh | ₹35.4 Cr | 77 | 4 | View details |
Products & Services of Schon Pharmaceuticals
Schon Pharmaceuticals offers a comprehensive portfolio of products and services, including Schon Pharmaceuticals Platform.
Manufacturer of syrup, capsules, tablets, injecatables and ointment
Board of directors of Schon Pharmaceuticals Limited (Schon Pharmaceuticals)
Schon Pharmaceuticals Limited is the primary company behind Schon Pharmaceuticals. The board of Schon Pharmaceuticals Limited currently have 4 directors; the longest-serving is Anil Bhatia, appointed in 1994. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anil Bhatia DIN 00437711 | Director | 30 Sep 1994 | 32 yrs | Schon Pharmaceuticals Limited |
| Sunil Bhatia DIN 00679341 | Director | 30 Sep 1994 | 32 yrs | Schon Pharmaceuticals Limited |
| Prashant Singh DIN 06853880 | Director | 01 Apr 2014 | 12 yrs 6 mo | Schon Pharmaceuticals Limited |
| Pooja Bhatia DIN 10292279 | Director | 28 Aug 2023 | 3 yrs 1 mo | Schon Pharmaceuticals Limited |
People of Schon Pharmaceuticals
1 people are tracked at Schon Pharmaceuticals (1 in leadership); the tracked headcount is 77.
| Name | Role | Group |
|---|---|---|
| CEO & MD | Leadership |
Complete people profiles for Schon Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Schon Pharmaceuticals
Figures of Schon Pharmaceuticals Limited, the primary company behind Schon Pharmaceuticals, for FY 2024. Revenue was ₹35.42 Cr (+7% year on year). Net profit was ₹57.1 Lakh (2% margin). EBITDA was ₹2.13 Cr (6% margin). Revenue has grown at a compounded annual rate of +11% over three years and +16% over five years.
- ₹35.42 CrRevenue · FY 2024 · +7% YoY
- ₹57.1 LakhNet profit · 2% margin
- ₹2.13 CrEBITDA · 6% margin
- ₹1.23 CrPaid-up capital
- 77Employees (provident fund records)
- +11%Revenue CAGR, 3 years
- +16%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Schon Pharmaceuticals Limited are on its company page.
Detailed financial statements for Schon Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Schon Pharmaceuticals
The website of Schon Pharmaceuticals (schonpharma.in) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 72.5% vs previous month
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Schon Pharmaceuticals (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Schon Pharmaceuticals
Schon Pharmaceuticals is headquartered in Indore, India. It is registered at Indore, Madhya Pradesh, India.
Anil Bhatia is the current CEO of Schon Pharmaceuticals.
Schon Pharmaceuticals has 77 employees.
The primary company behind Schon Pharmaceuticals, Schon Pharmaceuticals Limited, reported revenue of ₹35.42 Cr for FY 2024, up 7% year on year.
Schon Pharmaceuticals manufacturer of syrup, capsules, tablets, injecatables and ointment through providing healthcare solutions, traditional pharmaceuticals, traditional pharmaceuticals, and providing healthcare solutions. Prioritizing client-centric approaches, it ensures high-quality outcomes, innovation, and sustainable practices in its field. It continues to evolve, meeting industry challenges with strategic approaches.
Schon Pharmaceuticals offers Schon Pharmaceuticals Platform.
Schon Pharmaceuticals operates through Schon Pharmaceuticals Limited.
The legal entities of Schon Pharmaceuticals currently have 4 directors, including Anil Bhatia, Sunil Bhatia, Pooja Bhatia and others.